IRulya Therapeutics Inc.
IRLADrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
Apilimod Dimesylate Capsule
COVID-19 Disease
LAM-001
Pulmonary Hypertension Due to Lung Diseases and Hypoxia
LAM-002A
Amyotrophic Lateral Sclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Apilimod Dimesylate Capsule | Phase 2 | COVID-19 Disease | - | - |
LAM-001 | Phase 2 | Pulmonary Hypertension Due to Lung Diseases and Hypoxia | - | - |
LAM-002A | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in IRulya Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in IRulya Therapeutics Inc.'s (IRLA) pipeline across Phase 2. Its lead program is Apilimod Dimesylate Capsule (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IRulya Therapeutics Inc.'s next FDA catalyst?→
IRulya Therapeutics Inc.'s (IRLA) next tracked catalyst is a Earnings expected November 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IRLA biotech catalysts?→
Add IRLA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IRulya Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.